Robeco Schweiz AG Decreases Stock Position in AbbVie Inc. $ABBV

Robeco Schweiz AG cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 21.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,512 shares of the company’s stock after selling 7,140 shares during the quarter. Robeco Schweiz AG’s holdings in AbbVie were worth $5,907,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in ABBV. Marshall & Sullivan Inc. WA bought a new position in shares of AbbVie during the second quarter valued at about $25,000. Evolution Wealth Management Inc. purchased a new position in AbbVie during the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie during the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie in the 2nd quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. grew its position in shares of AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on ABBV. UBS Group reiterated a “neutral” rating on shares of AbbVie in a report on Tuesday. JPMorgan Chase & Co. boosted their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research report on Tuesday, November 4th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie Stock Up 0.2%

Shares of ABBV opened at $220.51 on Wednesday. The business’s 50 day moving average price is $226.84 and its 200-day moving average price is $216.04. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a market cap of $389.72 billion, a P/E ratio of 167.05, a P/E/G ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie’s payout ratio is currently 496.97%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a three‑year voluntary agreement with the U.S. administration that exempts the company from tariffs and future pricing mandates while committing to major U.S. investment — a headline that reduces policy/regulatory uncertainty and signals long‑term U.S. capital deployment. Read More.
• Positive Sentiment: AbbVie signed an exclusive global licensing deal (up to ~$5.6B) with RemeGen for RC148, a PD‑1/VEGF bispecific — this meaningfully expands AbbVie’s oncology pipeline and long‑term growth optionality. Read More.
• Positive Sentiment: AbbVie is buying a drug‑delivery system and Arizona manufacturing facility from West Pharmaceutical and is investing in U.S. manufacturing (including a reported $175M plant spend) — supports supply chain control and the company’s U.S. investment pledge. Read More.
• Neutral Sentiment: AbbVie joined peers in urging FDA updates to post‑approval change rules — could improve manufacturing flexibility but is a regulatory/industry‑wide request with uncertain timing. Read More.
• Neutral Sentiment: A Phase 2 bipolar depression study (ABBV‑932) reached completion — a development milestone that requires readouts for directional impact. Read More.
• Negative Sentiment: Under the U.S. deal AbbVie agreed to provide lower prices in Medicaid (and expand affordable offerings) — a meaningful concession that could weigh on near‑term revenue and margins for affected products. Read More.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.